Related Experiment Video

Updated: Jun 20, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Disparities in cancer clinical trials: an analysis of comprehensive cancer control plans

Tisha Moniek Felder1, Gabriela D Pena, Bridget F Chapital

  • 1Center for Health Promotion and Prevention Research, University of Texas School of Public Health, University of Texas Health Science Center-Houston, Houston, TX 77030, USA. Tisha.M.Felder@uth.tmc.edu

Preventing Chronic Disease
|September 17, 2009
PubMed
Abstract

Insights

Comprehensive cancer control plans often address clinical trial disparities, but few states with such plans mandate third-party reimbursement for trial participation. This highlights a gap in supporting equitable access to cancer research.

Area of Science:

  • Public Health
  • Cancer Control
  • Health Policy

Background:

  • Disparities in adult cancer clinical trial enrollment are significant.
  • The attention given to these disparities in comprehensive cancer control (CCC) plans is not well understood.

Purpose of the Study:

  • To assess how CCC plans address cancer clinical trial disparities.
  • To determine if CCC plans addressing disparities are linked to third-party reimbursement laws for clinical trial participation.

Main Methods:

  • Analysis of 57 CCC plans from Cancer PLANET and Cancerplan.org (2007).
  • Content analysis of plans for themes related to clinical trials and disparities.
  • Review of state third-party reimbursement laws for clinical trials (as of 2007).

Main Results:

  • 96% of CCC plans included content on clinical trials.
  • 71% of plans specifically addressed disparities.
  • Only 33% of plans addressing disparities were in states with third-party reimbursement laws.

Conclusions:

  • Many CCC plans acknowledge disparities in cancer clinical trials.
  • A significant gap exists between addressing disparities in plans and having supportive reimbursement policies.

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...